Pacylex Pharmaceuticals

04/24/2026

Pacylex was featured in a Nature Cancer article on new payloads for ADCs:
"Pacylex, too, is now exploring zelenirstat as an ADC payload, encouraged by preclinical data reported in November 2025 suggesting that the targeted approach could boost potency as much as 1,000-fold, enabling much lower effective doses."
- New payloads drive next-gen antibody–drug conjugates - Nature Cancer April 23, 2026

As tumor resistance to ADCs grows, new payloads are being investigated — from decades-old agents to newer drug classes such as immunotherapies and radioligands.

01/19/2026

What is a microsummit you ask? Come and find out as we present the key elements of Pacylex's novel ADC payload programs in under 3 minutes.

01/11/2026

Hope to see you at JP Morgan in San Francisco this coming week.

11/04/2025

At our poster in San Diego showing that Pacylex’s lead drug works great on ADCs, (antibody drug conjugates).

11/04/2025

Delighted to report the first positive ADC data using Pacylex's zelenirstat as a payload, being presented today at the World ADC Congress in San Diego. ADCs with zelenirstat were 20->1,000 fold more potent against prostate and breast cancer cell lines than zelenirstat alone including a breast cancer line resistant to most ADCs.
https://pacylex.reportablenews.com/pr/pacylex-pharmaceuticals-and-heidelberg-pharma-present-zelenirstat-antibody-drug-conjugate-data-at-the-16th-annual-world-adc?_gl=1*1hxfm9e*_gcl_au*MzAwNzk1NDg0LjE3NTU0NTcyMzQuMTcyNDM5NjU5Ni4xNzYyMjI4MjYyLjE3NjIyMjgyNzQ.

Edmonton, Alberta, Canada and Heidelberg Pharma, Ladenburg, Germany, November 4, 2025. Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company and world leader in developing N-myristoyltransferase inhibitors (NMTis) for cancer. Heidelberg Pharma AG (FSE: HPHA) is a clinical...

06/10/2025

Once again we head to BIO to meet with partners and seek new investors and partners for our oral zelenirstat in promising clinical trials in acute myeloid leukemia patients and our NMT inhibitor class of new ADC payloads.

Edmonton, Alberta, Canada June 10, 2025. Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company and world leader in N-myristoyltransferase inhibitors (NMTis) for cancer. Oral zelenirstat is a proprietary, potent, NMTi in clinical trials as a first-in-class treatment for he...

05/05/2025

AACR poster on zelenirstat from the lab of our CSO, Dr. Luc Berthiaume, with his grad student Rony Pain presenting.

05/05/2025

Headed to Boston to present our molecules as a new class of payloads for antibody drug conjugates (ADCs).

03/18/2025

Pacylex is proud to announce that we have begun dosing acute myeloid leukemia patients with oral zelenirstat. This is the indication we hope to bring to market first and for which we already have Orphan Drug and Fast Track designations.

Edmonton, Alberta, Canada March 17, 2025. Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company and world leader in developing N-myristoyltransferase inhibitors (NMTis) for cancer. Oral zelenirstat is under clinical investigation as a first-in-class targeted therapy for t...

02/03/2025

February is a surprisingly busy time for investor conferences building on the momentum of JP Morgan Healthcare week in January. Pacylex is involved in three in the next two weeks.

Edmonton, Alberta, Canada February 3, 2025. Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company and world leader in developing N-myristoyltransferase inhibitors (NMTis) as targeted therapies for cancer. Oral zelenirstat is in development for the treatment of hematologic...

12/09/2024

Wonderful article on Pacylex today from University of Albert in their Folio newsletter:

University of Alberta spinoff Pacylex has spent 12 years pushing its first-in-class cancer treatment forward from a research lab idea to the stage of Phase 2 human trials with the potential to benefit people with both blood and solid tumours. It would not have happened without teamwork between scien...

11/07/2024

We are very pleased to welcome Michael Kamdar, an experienced biotech executive and deal maker to the Pacylex Pharmaceuticals Board of Directors.

Edmonton, Alberta, Canada November 7, 2024. Pacylex Pharmaceuticals Inc. (Pacylex) is the only clinical-stage pharmaceutical company developing N-myristoyltransferase inhibitors (NMTis) as targeted therapies for the treatment of hematologic cancers. Pacylex also offers NMTis as payloads for antibody...